|54.69||-0.3500||-0.64%||Vol 1.12M||1Y Perf 27.16%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||63.38||Analyst Rating||Strong Buy 1.40|
|Potential %||15.89||Finscreener Ranking||★★★★ 53.42|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 51.58|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 58.54|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||3.82B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||83.98||Earnings Date||29th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||29th Apr 2021|
|Estimated EPS Next Report||-1.23|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||772.20K|
|Avg. Monthly Volume||828.83K|
|Avg. Quarterly Volume||771.59K|
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock closed at 54.69 per share at the end of the most recent trading day (a -0.64% change compared to the prior day closing price) with a volume of 1.12M shares and market capitalization of 3.82B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 562 people. Agios Pharmaceuticals Inc. CEO is Jacqualyn A. Fouse.
The one-year performance of Agios Pharmaceuticals Inc. stock is 27.16%, while year-to-date (YTD) performance is 26.22%. AGIO stock has a five-year performance of 12.58%. Its 52-week range is between 32.47 and 58.93, which gives AGIO stock a 52-week price range ratio of 83.98%
Agios Pharmaceuticals Inc. currently has a PE ratio of -11.20, a price-to-book (PB) ratio of 9.22, a price-to-sale (PS) ratio of 31.41, a price to cashflow ratio of 50.40, a PEG ratio of 2.32, a ROA of -35.92%, a ROC of -59.31% and a ROE of -59.69%. The company’s profit margin is -%, its EBITDA margin is -167.40%, and its revenue ttm is $116.10 Million , which makes it $1.66 revenue per share.
Of the last four earnings reports from Agios Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.23 for the next earnings report. Agios Pharmaceuticals Inc.’s next earnings report date is 29th Apr 2021.
The consensus rating of Wall Street analysts for Agios Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $63.38, which is +15.89% compared to the current price. The earnings rating for Agios Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Agios Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Agios Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.59, ATR14 : 2.82, CCI20 : 118.12, Chaikin Money Flow : 0.06, MACD : 0.84, Money Flow Index : 54.99, ROC : 11.05, RSI : 52.91, STOCH (14,3) : 86.56, STOCH RSI : 0.87, UO : 52.46, Williams %R : -13.44), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Agios Pharmaceuticals Inc. in the last 12-months were: Andrew Hirsch (Option Excercise at a value of $0), Carman Alenson (Option Excercise at a value of $0), Carman Alenson (Sold 250 shares of value $9 983 ), Christopher Bowden (Option Excercise at a value of $125 978), Christopher Bowden (Sold 3 583 shares of value $179 200 ), Darrin Miles (Option Excercise at a value of $0), Darrin Miles (Sold 2 700 shares of value $129 868 ), David P. Schenkein (Option Excercise at a value of $0), David Scadden (Option Excercise at a value of $0), Ian T. Clark (Option Excercise at a value of $0), Jacqualyn A. Fouse (Option Excercise at a value of $0), John M. Maraganore (Option Excercise at a value of $0), Kaye I. Foster-Cheek (Option Excercise at a value of $0), Maykin Ho (Option Excercise at a value of $0), Paul J. Clancy (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.